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Summary 
T  cell receptor (TCR)-recognizing regulatory cells, induced after vaccination with self-reactive 
T  cells  or TC1K peptides, have been shown to prevent autoimmunity. We have asked whether 
this regulation is involved in the maintenance  of peripheral  tolerance to myelin basic protein 
(MBP) in an autoimmune disease model, experimental  autoimmune encephalomyelitis  (EAE). 
Antigen-induced EAE in (SJL  X  B10.PL)F1 mice is transient in that most animals recover per- 
manently from the disease.  Most of the initial encephalitogenic T  cells recognize MBP Acl-9 
and predominantly use the TCR V[38.2 gene segment. In mice recovering from MBP-induced 
EAE, regulatory CD4 + T  cells (Treg) specific for a single immunodominant TCR  peptide B5 
(76-101)  from  framework  region  3  of the  V[38.2  chain,  become  primed.  We  have  earlier 
shown that cloned B5-reactive Treg can specifically downregulate responses to Acl-9 and also 
protect mice from EAE.  These CD4 Treg clones predominantly use the TCtL V[314 or VI33 
gene segments.  Here we have directly tested whether deletion/blocking of the Treg from the 
peripheral  repertoire  affects the spontaneous recovery from EAE.  Treatment  of F1  mice with 
appropriate V[3-specific monoclonal antibodies resulted in an increase in the severity and dura- 
tion of the disease: even relapses were seen in one-third to one-half of the Treg-deleted mice. 
Interestingly,  chronic disease in treated mice appears to be due to the presence of Acl-9-spe- 
cific T  cells.  Thus, once self-tolerance to MBP is broken by immunization with the antigen in 
strong adjuvant,  TCR  peptide-specific  CD4 Treg cells participate  in reestablishing peripheral 
tolerance. Thus, a failure to generate Treg may be implicated in chronic autoimmune conditions. 
F 
or  most  of the  history  of immunology,  it  had  been 
thought that the modus operandi of the immune system 
required  discrimination  between  self and  nonself,  leading 
to a prevention of response to the former. The presence of 
self-reactive  T  ceils  and  the  primacy of self-recognition is 
now considered essential for the normal functioning of the 
immune system. Indeed, since positive selection is based on 
recognition of self-peptides in a self-MHC context, to one 
extent or another,  it is clear that responses to foreign anti- 
gens  depend  on  cross-reactivity with  self (1-3).  The  ease 
with which self-reactive T  cells  can be detected in normal 
individuals  is  one  indication  that  negative  selection  is  in- 
complete  and  that  other  mechanisms  must  operate  subse- 
quently to maintain peripheral tolerance to self. 
Therefore,  self-tolerance  to  at least  some  tissue-specific 
antigens is not entirely a passive process but rather an active 
dynamic state in which potentially pathogenic self-reactive 
T  cells are prevented from causing disease by other regula- 
tory T  cells  (4).  The differential  secretion  of lymphokines 
by T  cell subsets offers an explanation for the ability of cer- 
tain T  cells to induce autoimmunity and others to regulate 
these  autoreactive  T  cells  (5).  Thl  cytokines  have  been 
shown  to  be  involved in  cell-mediated  autoimmune  dis- 
eases.  For example,  IFN-~/, lymphotoxin, or TNF-o~ secre- 
tion correlate with the  encephalitogenic  capacity of T  cell 
clones  reactive  to myelin basic protein  (MBP) 1 (6).  Anti- 
TNF-cl antibodies have been shown to inhibit experimen- 
tal  autoimmune  encephalitis  (EAE)  and  collagen-induced 
arthritis  while  anti-TGF-[3  accelerates  the  disease  (re- 
viewed in 4,  5).  Both TGF-[3  and  IL-10 can play an im- 
portant role in regulating autoimmune inflammatory reac- 
tions. 
Similarly, ifimmunoregulatory mechanisms malfunction, 
the resulting deficiency of regulatory T  cells could lead to 
autoimmunity.  For example,  depletion  of a particular sub- 
set of T  cells  results in thyroiditis in mice (7);  athymic rats 
reconstituted  with  CD45RB  high CD4 +  T  cells  alone  de- 
velop  a severe  autoimmune  condition but when reconsti- 
tuted  with  both  CD45R~ high and  regulatory  CD45RB  l°w 
1Abbreviations used in this paper: EAE, experimental autoimmune encepha- 
lomyelitis; MBP, myelin basic protein; PPD, purified protein derivative 
of mycobacterium tuberculosis; PTx, pertussis toxin; Treg, regulatory 
CD4 + T cells. 
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These and other neonatal depletion and reconstitution ex- 
periments suggest that a  determining factor in the  expres- 
sion ofautoimmunity is the equilibrium between autoreac- 
tive and regulatory T  cells (9). 
EAE  is  a  T  cell-mediated autoimmune  demyehnating 
disease of the  central nervous  system that  can be induced 
after  immunization  with  MBP  or  its  peptide  fragments. 
The  TC1Ks  of MBP-reactive  T  cells in  several strains  of 
mice and rats have been shown to be encoded by a limited 
set  of V-region  gene  segments  (10-13).  After immuniza- 
tion  with  MBP,  most  CD4 +  T  cells in  B10.PL  or  PL/J 
mice  recognize the immunodominant  NH2  terminal pep- 
tide Acl-9 and a  majority of CD4 ÷  T  cells use the  TCR 
V]38.2  gene  segment  (10,  11).  The  limited  repertoire  of 
TCR  V  genes engaged in response to MBPAcl-9  has al- 
lowed the use of mAbs to V[38 in vivo to successfully pre- 
vent or treat EAE (10,  11). 
Regulatory responses capable of protecting animals from 
autoimmunity can be  raised to  the V  region of the  TCR 
after vaccinafon with disease-causing, MBP-reacfve  CD4 + 
T  cells or  more  recently,  after immunization  with  TCR 
peptides  from  the  CDR  II  (amino  acids  39-59)  or  the 
framework III (amino acids 76-101)  region of the TCIK-]3 
or the CDR  III region of the TCP,-ot chain of encephali- 
togenic T  cells (14-17).  We have clearly established in the 
murine model that protection from EAE by TCt< peptides 
can be mediated by regulatory T  cells that are physiologi- 
cally induced after MBP or Acl-9 immunization (18). We 
have  characterized  TCR  peptide-reactive  T  cells  at  the 
clonal level and  their physiological role during the  course 
of EAE. We have studied the dynamics of the spontaneous 
physiological induction of anti-TCR-peptide responses dur- 
ing EAE  in  B10.PL  mice.  It  was  shown  that  T  cells di- 
rected  against  the  dominant  TCR-peptide  of V138.2,  B5 
(76-101),  generally  were  primed  during  recovery  from 
MBP-  induced  EAE  without  the  necessity  for  external 
challenge  by  TCR  peptides.  We  have  isolated  V]314- 
expressing T  cell lines, clones, and T  cell hybridomas spe- 
cific for B5, a peptide encompassing framework region 3 of 
the  V~8.2  chain.  These  T  ceils were  CD4 +,  CD8-,  and 
MHC  class II restricted.  In adoptive transfer experiments, 
B5-reactive T  cell clones, but not B4-specific T  ceils, spe- 
cifically inhibit proliferative responses to Acl-9 and protect 
mice from MBP-induced EAE. 
Here  we  have  asked  whether  physiologically activated 
TCP,-peptide  B5-specific T  cells are  directly involved in 
mediating spontaneous recovery in (SJL  ×  B10.PL)F1  mice. 
F1  mice  were  chosen  for  their  consistent  acute  disease 
course  (<10%  of animals develop chronic  symptoms)  and 
high  disease-incidence to MBP  Acl-9-induced EAE.  We 
show that after treating animals with mAbs against specific 
V]~-chains,  predominantly  used  by  regulatory  CD4 +  T 
cells  (Treg)  cells,  there  is  delayed recovery and  the  mice 
contract  chronic  EAE.  Upon  reconstitution  with  cloned 
B5-specific T  cells these V]3-depleted mice showed an ac- 
celerated  recovery.  Thus,  TCR-peptide  specific  CD4  T 
cells that are spontaneously primed in F1 mice are involved 
in mediating spontaneous recovery from EAE. These find- 
ings describe the protective role of Treg cells in restoring 
peripheral tolerance and preventing outbreaks of EAE. We 
conclude that chronic and relapsing disease could be due to 
defective regulation. 
Materials  and  Methods 
Mice.  SJL and B10.PL mice were purchased from The Jack- 
son Laboratory, Bar Harbor, ME.  (SJL ×  B10.PL)F1  mice were 
bred under specific pathogen-free conditions in our own colony. 
Female mice were used at 8-14 wk of age. 
Antibodies.  The  following mAbs  were  used:  anti-CD4-PE 
(GK1.5 from Becton Dickinson and Co., Mountain View, CA), 
anti-Vf~14  (14-2, rat IgiVl, 19), anti-V[35  (20), and anti-V[33  (KJ- 
25, 21). Anti-V]314 (14-2) antibodies acquired from PharMingen 
contained 0. i % (wt/vol) sodium azide. Two control experiments 
were done to rule out any effect ofazide on EAE: first, a desalting 
column was used to purify this IgM molecule; second, an equal 
amount of azide in saline (50-100  lal of 0.1%  solution) was in- 
jected in control animals with no effect on EAE. The hybridomas 
producing anti-V]38.2 and anti-V]314 antibodies were generously 
provided by Drs. Michael Bevan (University of Washington, Se- 
attle), and David Raulet (University of California, Berkeley), re- 
spectively. Since only a single anti-Vf314 mAb, 14-2, is available, 
attempts were made to differentiate simple receptor blocking vs 
depletion after antibody injection by in vitro culture of peripheral 
T  cells with recombinant IL-2. 3 d after antibody injections, at a 
time when apparent depletion was detected (see Table 2), nucle- 
ated splenic cells were collected from mice given a single injec- 
tion of the mAb and divided into two fractions. One fraction was 
immediately stained, whereas the other was cultured for 72-96 h 
with rlL-2 and then stained with anti-TCR monoclonals. The 
proportion  of cells  in  each  fraction  that  stained positively for 
V[314 was compared and found to be similar (0.5 vs 0.7), suggest- 
ing depletion of T cells. 
TCR Peptides.  TCR  peptides  used  were  same  as  reported 
previously (17,18)  and were synthesized by S. Horvath (Caltech, 
Pasadena, CA) using a solid-phase technique on a peptide synthe- 
sizer (model 430A;  Applied Biosystems, Inc.,  Foster City,  CA) 
and were purified on a reversed-phase column by HPLC (22). 
Splenic Proliferation Assay.  Spleens  of mice  were  removed 
25-35 d after immunization and a single cell suspension was pre- 
pared. Splenocytes (8 ×  105 cells/well) were cultured in 96-well 
microtiter plates in 200  btl of serum free medium  (HL-1; Ven- 
trex, Portland, ME)  supplemented with 2  mM glutamine; pep- 
tides were added at concentrations ranging from 0.1  to 7 b~M fi- 
nal concentration. Proliferation was assayed by addition of 1 ~,Ci 
[3H]thymidine (International Chemical and Nuclear, Irvine, CA) 
for the last  18 h of a 5-d culture, and incorporation of label was 
measured by liquid scintillation counting. 
Induction of EAE.  For induction of EAE, mice were immu- 
nized subcutaneously with 100 I,  tg Acl-9 emulsified in CFA and 
0.15  ~g pertussis toxin (PTx)  (List Biological Laboratories, Inc., 
Campbell, CA) was injected in 200  I~1 saline intravenously 48 h 
later. Mice were observed daily for signs of EAE until >60-90 d 
after MBP  Acl-9  immunization.  Mice  for  some  of the  initial 
Treg-deletion  experiments  were  monitored  in  a  double-blind 
manner by two independent observers. The average disease score 
for each group was calculated by averaging the maximum severity 
of all of the affected animals in the group. Disease severity was 
scored on a five-point scale (18): 1, flaccid tail; 2, hind limb weak- 
ness; 3, hind limb paralysis; 4, whole body paralysis; 5, death. 
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Figure  1.  T  cells reactive  to the immunodominant TCR peptide  B5 
become primed in mice recovering from EAE.  (SJL ×  B10.PL)F1  mice 
were immunized with MBP or Acl-9/CFA and PTx (48 h later). 25--35 d 
later, the proliferative recall responses to the immunogenic TCP,. peptides 
from the V[38.2 chain were tested in the spleen. There was no prolifera- 
tion to TCR peptides in spleen cells from unimmunized  F1 mice. By 30 d, 
at the time of assay, mice had recovered from paralysis. R.esponses in indi- 
vidual mice (a total of 21  mice) to medium alone  (A), B2 (I~), and B5 
(0)  at an optimum concentration  (3 IxM) are shown.  The data are ex- 
pressed  as  arithmetic  means  of [3H]thymidine  incorporation  (cpm  × 
10  3) in triplicate cultures. These data have been pooled from five indi- 
vidual experiments. 
Flow Cytometry and Cell Sorting Analysis.  Antibodies were  ei- 
ther purified from hybridoma supernatants  by protein A chroma- 
tography  or from ascites using gel-exclusion chromatography,  as 
recommended by the manufacturers  (Middlesex Sciences, Mans- 
field,  MA).  Some  antibodies  were  biotinylated  with  NHS-LC- 
Biotin  (Pierce  Chemical  Co.,  Rockford,  IL)  according  to  the 
manufacturer's recommendations. For cell staining, antibodies were 
used  in  PBS  containing  1%  fetal bovine  serum.  106  cells  were 
stained with 0.5 txg of antibody in a total volume of 50 t~1 at 4°C 
for 30 rain.  Cells were washed  twice with PBS and  then resus- 
pended  in  50  ILl of a  1:50  dilution  of either  FITC-conjugated 
streptavidin or goat anti-mouse  Ig-FITC (Southern  Biotechnol- 
ogy Association, Birmingham, AL). After 20 n-fin at 4°C, cells were 
washed,  fixed with  1% paraformaldehyde  in PBS,  and  analyzed 
using  a  cytofluorograph  (Becton  Dickinson  and  Co.,  Mountain 
View, CA). 
Tolerance Induction.  Tolerance to TCR  peptides was induced 
by two intraperitoneal injections at different doses,  14 or 50 nmol 
ofpeptides in IFA (50 Ixl), the first within 24 h after birth and the 
second 72 h  after birth.  7-8 wk later, tolerized animals were im- 
munized either with TCR  peptides/CFA for proliferative T  cell 
responses or with Acl-9/CFA/PTx for the induction of EAE. In 
one  experiment,  tolerized  mice  (8  wk  old)  were  subsequently 
vaccinated  with  TCR  peptides  to  study  protection  from  EAE. 
Antigen-specific tolerance  to MBP peptides was  induced by in- 
travenous injection of 400 Ixg peptide in 0.2 ml PBS, as described 
previously (23). 
Results 
Spontaneous  Priming  of TCR Peptide B5-reactive  T  Cells in 
(SJL ×  BIO.PL)F1 Mice after Antigen Injection.  To test whether 
TCR-peptide  B5-specific T  cells become naturally primed 
during recovery from antigen-induced  EAE in the  (SJL  × 
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Figure 2.  Selection ofV~14 + CD4 + T cells in the B5 response in vivo. 
Splenic T cells from F1 mice recovered from MBP-induced EAE were re- 
moved, stained, and sorted by FACS® into V1314-positive (A) and -nega- 
tive  (B)  CD4  cells using fluorescence-labeled mAbs. Sorted  populations 
were stimulated with the indicated peptides or with PPD and syngeneic, 
3,000  rad-irradiated  spleen cells. Cultures  were pulsed with  [3H]thymi- 
dine 72 h later and proliferation is shown as the mean values ofthymidine 
uptake in triplicate cultures over the next 24 h. 
B10.PL)F1  mouse  as well as in the B10.PL  strain  (18),  the 
specific proliferative response to B5 was followed in splenic 
T  cells from  mice  challenged  25-35  d  earlier with  MBP/ 
CFA  and  PTx.  A  proliferative  T  cell response  to  another 
TCI< peptide B2,  as control,  was also followed in parallel. 
Clearly, a significant proliferative response to TCR  peptide 
B5 was revealed in the peripheral T  ceils from mice recov- 
ering from EAE (Fig.  1).  In contrast,  there was no prolifer- 
ative  recall  response  to  another  proliferation-inducing  or 
immunogenic TCR. peptide, B2. Also, no proliferation was 
detected  in  response  to  B5  in  unimmunized  mice  or  in 
MBP/CFA/PTx-immunized  mice before the onset of EAE 
(data not shown).  Thus,  during the course of recovery from 
antigen-induced EAE, T  cells reactive to the immunodom- 
inant framework region 3  TClq, peptide of the V[38.2 chain 
are  generated  in  (SJL  ×  B10.PL)F1  mice,  consistent  with 
our earlier observations in the B10.PL strain  (18). 
Selection of V~14 +, CD4 + T  Cells In  Vivo.  Our  previous 
analysis of 29 B5-specific B10.PL-derived T  cell clones and 
hybridomas,  showed an oligoclonal TCR  VI3 gene usage: 
a distinct majority (26/29)  ofT  cells used V[314;  three used 
VI33 gene segments  (18).  To investigate the in vivo signifi- 
cance  of this  observation  (without  introducing  a  bias  as  a 
result  of in vitro long-term growth  and selection), periph- 
eral  T  cells  from  mice  recovering  from  antigen-induced 
EAE were sorted into VI314 +  CD4 +  and V[314-  CD4 +  T 
cell populations.  Sorted populations  were  incubated  in the 
presence  of irradiated  spleen cells from naive F1  mice with 
optimum  concentrations  of different peptides  and the pro- 
liferative response was determined  (Fig. 2).  A  major prolif- 
erative response to B5, but not B2 was found in the V[314 + 
CD4 + T  cell population.  The diminutive response to B5 in 
the V~14-  fraction  could be due to the presence  ofV~3 + 
T  cells in  this  population.  Because  of a  very low yield  of 
VI33 +  CD4 +  T  cells,  we  could  not  do  a  similar  analysis. Table 1.  Neonatal Tolerance Induction to TCR Peptides 
T  cell proliferative responses 
Treatment  B4  B5  PPD 
Incidence of EAE 
(maximum disease 
score) 
clam ×  1,000 
PBS-tolerized  50.3  _+  1.2  77.8  +  9.1  112.5  _+ 4.1  4/5(5,4,3,3,0) 
41.2  +  5.2  91.4 _+  1.0  97.8  _+  10.5 
B4-tolerized  2.1  -+ 1.7  95.1  +  1.2  150.5  -4- 11.2  6/6(5,4,4,4,4,1) 
4.0 -+ 1.2  112.2  _+ 5.7  144.2  _+ 9.8 
B5-tolerized  61.5  +  5.1  67.7  _+  10.1  92.5  _+  1.2  6/7(5,5,4,3,1,1,0) 
73.5  _+  11.2  58.8  -+ 5.3  118.5  _+ 5.6 
Neonatally tolerized mice (two from each group) were challenged (emulsified in CFA) and in vitro recalled with TCR peptides, B4 and B5. LN 
proliferative responses at optimum concentration  ofTCR peptides (7 IxM) are shown. Remaining mice in each group were immunized with Acl- 
9/CFA/PTx to induce EAE. 
Both populations showed a comparable response to the pu- 
rified protein derivative of Mycobacterium  tuberculosis. 
Tolerance Induction in CD4 Treg Populations.  To directly test 
for  the  functional  consequences  of the  response  to  t35  in 
recovery from EAE,  attempts were  made to induce toler- 
ance  in  the  CD4  Treg population.  Groups  of mice  were 
neonatally tolerized with  TCR  peptides, B4,  B5,  or PBS 
(Table  1).  7-8  wk later, two  mice from  each group  were 
challenged with the same peptides in CFA to test for prolif- 
erative responses. The remaining mice in each group were 
challenged with  Acl-9/CFA/PTx  to  induce EAE.  T  cell 
proliferation in the draining LN populations in response to 
TCR  peptides or purified protein derivative of mycobacte- 
rium tuberculosis (PPD)  are shown in Table 1.  Mice neo- 
natally tolerized to  B4  and  subsequently  challenged with 
B4  did not proliferate.  In contrast,  B5-tolerized mice  still 
showed  a  robust  proliferative  response  to  a  subsequent 
challenge with  B5.  Responses  to  PPD  were  similar in  all 
groups. In a separate experiment mice tolerized at a higher 
antigen level, with 50 nmol orB5, still showed a prolifera- 
tive reponse to B5  (data not shown).  The  results showing 
that the incidence and severity of EAE  in each group was 
very similar (Table  1)  indicate that B5-specific T  cells are 
not easily tolerized. Likewise, there was no functional tol- 
erance induced and  "B5-tolerized" mice  could be signifi- 
cantly protected from EAE by subsequent vaccination with 
B5  as adults. This inability to induce neonatal tolerance to 
B5 along with the oligoclonality of the TCR  V-gene usage 
led us  to  use  the  antibody-depletion approach  to  test  di- 
rectly the role ofB5-reactive T  cells in recovery from EAE. 
Injection  of  V~-Chain-specific  mAbs  Leads  to  a  Significant 
Temporary  Depletion  of Corresponding  V~-expressing  T  Cells. 
Anti-TCR V[~ region-specific antibodies were used to de- 
plete  specific  T  cells  in  vivo.  We  initially used  various 
amounts  (25-250  Ixg)  of anti-V~14  and/or anti-V[33  (0.2 
ml vol) to inject (SJL ×  B10.PL)F1  mice, intraperitoneally. 
3 d later, peripheral T  cells were analyzed by flow cytome- 
try. Injection of 50-100 p~g of anti-V[314 or anti-V[33 anti- 
body was  sufficient  to  deplete  the  corresponding  T  cells 
considerably (Table 2). A  small population ofT  cells repre- 
senting ~15%  of the original level of CD4 V[314-express- 
ing T  cells persisted after antibody injections and was  not 
deleted even after injection with 250  txg of antibody. Since 
mAb 14-2 is IgM and is a rat-mouse hybrid, depletion may 
be inefficient owing to induction of an anti-rat immune re- 
sponse. Peripheral T  cells from some mice were examined 
for the presence ofV1314 CD4 T  cells at 2, 3, and 6 wk af- 
ter antibody injection. Although at 2  wk a similar staining 
pattern to that after 3 d was seen, by 3 wk, normal levels of 
V[314  T  cells  had  almost  returned.  Thus,  depletion  of 
V1314-expressing  T  cells after  a  single injection with  the 
mAb is incomplete and appears to be relatively short term. 
Anti- V~14 and Anti- V~3-treated  Mice Develop Severe Chronic 
EAE.  We  had  shown  earlier  that  cloned  B5-specific 
CD4  V[314  T  cells,  when  adoptively  transferred  into 
Table 2.  Down-modulation of V~314 and V~3 T Cells after 
Treatment of (SJL ×  BIO.PL)F1 Mice with Anti-V~14 or Anti- 
V~3 mAbs 
Antibody 
treatment  Amount  V1314 T cells  V133 T cells 
/xg  %  % 
Ig control  250  2.8  0.9 
14-2  250  0.5  1.1 
14-2  100  0.6  0.8 
14-2  50  0.5  1.1 
KJ-25  250  2.8  0.5 
KJ-25  100  2.9  0.4 
Various concentrations of either 14-2 (anti-V[314) or KJ-25 (anti-V[33) 
were injected i.p. into groups of (SJL × B10.PL)F1 mice. 3 d later, nu- 
cleated spleen cells were passed over nylon wool and stained with bio- 
tinylated 14-2 or KJ-25 antibodies, followed by streptavidin-FITC  and 
CD4-PE. Cells were analyzed by flow cytometry. 
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Figure  3.  Mice treated with 
anti-V{314 and  anti-V[33 anti- 
bodies  display chronic disease 
and  recover poorly from anti- 
gen-induced EAE. Four groups 
(five in each) of F1  mice were 
immunized  with  Acl-9/CFA/ 
PTx for the induction of EAE. 
24 h after Acl-9 injection, 50- 
100 ~g of various mAbs in 200 
ILl saline  were injected intraperi- 
toueally. Mice were monitored 
daily by  two  independent ob- 
servers for disease until day 70. 
(A) control antibody, Rat  lgM; 
(B)  anti-V[33; (C)  anti-V[314; 
(D) anti-V[314  and anti-V[33. 
B10.PL mice, were  able to  down-regulate encephalitoge- 
nic MBP-reactive T  cells and prevent MBP-induced EAE 
(18). Alternatively, mice could be vaccinated with peptide 
B5  and  could also  be  significantly protected  from  MBP- 
induced EAE (17). To directly assess the physiological role 
ofV[314 + and/or V[33 + CD4 + Treg in spontaneous recov- 
ery from EAE, we have asked whether depletion/blocking 
of these cells affects  the duration of disease in F1 mice. 
To obtain a reproducible disease course from experiment 
to  experiment,  (SJL ×  B10.PL)F1  mice were  immunized 
subcutaneously with 100 ~g of Acl-9 emulsified with CFA 
(no additional M.  tuberculosis was added), followed by a sin- 
gle intravenous injection of 150 ng of PTx in saline, 48 h 
later. Disease incidence in this protocol was 90-100% and 
most of the animals (90-95%) showed an acute episode of 
EAE with spontaneous recovery.  For antibody treatment, 
mice were divided into several groups: mice in one group 
were left untreated, whereas others were injected with var- 
ious mAbs on the same day or 24 h  after Acl-9/CFA in- 
jection. Results from one experiment are shown in Fig. 3, 
and the data from three different experiments are summa- 
rized  in Table 3.  Mice  treated  with  anti-V[314 and anti- 
V~33 mAb had  severe  and chronic EAE,  with most mice 
(9/9)  recovering very  slowly.  In fact,  some  of the  mice 
(30-45%) in the anti-V[314-treated group showed relapses 
and most recovered much later (days  48-70)  than mice in 
the control groups (around day 25-30). Mice treated with 
anti-V[33 only showed no obvious changes in their recov- 
ery  pattern  and  were  similar  to  the  control  Ig-treated 
group. Mice were also treated with an irrelevant anti-TCR 
(V[35.1)  antibody, as  a  control group,  with no significant 
effect on EAE  (Table 3).  It is clear that after a single anti- 
V[3 antibody injection, mice did recover eventually (in dig 
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ferent experiments from days 48-70). In one experiment in 
which  we  injected mice  on days  1,  14,  28,  and 42  with 
both anti-Vf314 and anti-V[33 antibodies, recovery was fur- 
ther delayed in that 4/5 mice showed partial paralysis beyond 
day 70  (data  not shown).  Interestingly, mice in the  com- 
bined anti-V[314- and anti-V[33-treated group did not stay 
severely sick (e.g., with a score of 4) but remained partially 
paralyzed in the tail and hind limbs (score 1 and 2). 
Table 3.  Chronic  EAE in Mice Treated with anti-TCR 
Antibodies 
Incidence of  Disease  Average  Incidence of 
Treatment  acute EAE  onset  score  chronic EAE* 
day  I5  d  day 35 
None  9/11  10-13  2.8  0/11 
Ig control  8/10  9-14  2.7  1/10 
Anti-VI33  8/11  10-13  2.9  1/11 
Anti-V[35  5/5  9-12  3.0  0/5 
Anti-VI314  16/17  9-13  3.4  11/17 
Anti-V1314 + 
Anti-VJ33  9/9  9-14  3.6  9/9 
Age-matched female (SJL x  B10.PL)F1 mice were treated intraperito- 
neally with various mAbs (50-100 Ixg/mouse) either on the same day of 
Acl-9/CFA injection, or 24 h later in 200 Ixl saline. PTx (150 ng) was 
given i.v. 48 h after acl-9 injection in 200 Ixl saline. 
*P values between the control group (monophasic disease) and anti- 
V~14/anti-V~3-treated  group (chronic disease with delayed recovery) 
was P <0.001,  and was calculated using the chi-square test with Yates 
correction. til 
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Figure 4.  Adoptively  transferred Treg clone  B5.2 accelerates recovery 
in Treg-depleted mice. Three groups of F1 mice were injected  with Ac 1- 
9/CFA/PTx for EAE and were treated with anti-V~14 antibody as in 
Fig. 3 C. On day 12, at the time of onset of EAE, mice were injected in- 
traperitoneally  with either saline  only (A), or with 106 B4.1 T cells (B), or 
with 106 B5.2 T cells (C). The disease was monitored as in Fig. 3. 
terminant, was injected in CFA with PTx, it was capable of 
causing EAE in B10.PL mice as well as in F1 mice (25, and 
Kumar,  V.,  unpublished observation).  It  is  not  yet  clear 
whether in vivo-primed T  cells specific for these later de- 
terminants are encephalitogenic and/or participate in chronic 
EAE in this system. 
We wanted to  test whether chronic disease or even re- 
lapses in some cases  (30-45%) in the anti-V~-treated mice 
were due to the presence of T  cells with specificities for 
determinants other  than Acl-9, namely subdominant de- 
terminants, such as MBP81-100/A  ~ or MBP121-140/A  u. 
T  cells specific for these determinants do not predominantly 
use  V[38.2  or  V[313  gene  segments,  which  are  prevalent 
among Acl-9~specific T  cells.  Therefore, anti-V[314/anti- 
V[33-treated mice were depleted of Acl-9~pecific T  cells 
during the course of chronic EAE and their disease and re- 
covery were followed. As shown in Table 4,  mice in the 
control group, with Acl-9-specific T  cells intact, showed 
chronic EAE in that 7/7 mice still had clinical signs of the 
disease by day 35. In contrast, mice devoid of Acl-9-reac- 
tive T  cells  (anti-V[38.2- and anti-V~13-treated) showed 
accelerated recovery, despite the loss of Treg,  and despite 
the presence of T  cells directed to the subdominant deter- 
minant  of MBP.  Only  1  Out  of  9  mice  in  this  group 
showed clinical EAE by day 35. 
Since non-Acl-9-reactive T  cells, including T  cells spe- 
cific for other myelin antigens, could use V~8 +  or V[33 + 
TCR, we induced antigen-specific tolerance and studied its 
effect  on  the  chronicity of EAE  in  Treg-depleted mice. 
Adoptive  Transfer  of the B5-specific,  V~ 14-expressing  Regu- 
latory  T  Cell  Clone  B5.2  Accelerates  Recovery  in  Anti-VAg- 
treated F1 Mice.  We  next  wanted to  test  whether  adop- 
tively transferred B5-specific Treg cells could reestablish a 
regulatory balance and normalize the disease  course in Treg- 
depleted  mice.  First,  groups  of mice  (SJL  ×  B10.PL)F1 
were treated with anti-V~14 antibody, intraperitoneally, as 
in  Fig.  3.  Mice  in  one  of the  anti-V[314-treated groups 
were injected (i.p.) with 106 cloned B5.2 T  cells at the time 
(day  12)  of onset of EAE.  Mice in the  other two  groups 
were injected with either saline or with a B4-specific T  cell 
clone, B4.1  (106).  As shown in Fig. 4,  mice injected with 
the B5.2 clone recovered much earlier (4/5 mice recovered 
by  day  36)  than  mice  in  the  control  anti-V[314  treated 
group  (0/5  by day 36).  Mice in the  B4.1-injected group 
failed  to  recover  in  an  accelerated  fashion.  It  should  be 
pointed out that at ~2  wk after injection, the  anti-VI314 
apparently had reduced to an ineffective level, so that the 
transferred B5.2  cells manage to  perform their regulatory 
functions. 
Chronic Disease and Relapses  in Anti-V~8-treated  Mice Are 
Due  to  the Presence of Dominant  Peptide Acl-9-specific  T  Cells. 
We have shown earlier that T  cells specific for other sub- 
dominant determinants appear late in F1 mice after immu- 
nization with Acl-9  (24).  Recently, we  have shown that 
when peptide MBP121-140, containing a subdominant de- 
Table 4.  A  Chronic Disease Course in Anti- V~-treated 
Mice Can Be Attributed  to the Continued  Presence of Ac l-9-specific 
T  Cells 
Average 
Incidence of  clinical  Incidence of 
Treatment  acute EAE  score  chronic EAE 
day 14  day 35 
Experiment 1 
Ig control  7  3.1  7/7 
Anti-VI38.2  + 
Anti-VI313  9  3.4  1/9" 
Experiment 2 
MBP 41-58  5  2.9  5/5 
MBP Acl-9  5  3.0  0/5* 
Groups of (SJL  ×  B10.PL)F1 mice treated with both anti-V[314 and 
anti-V[33 mAbs and matched for the severity of EAE symptoms were 
treated at day 14 after disease onset with, in experiment 1, i.p., either an 
IgG control Ab or a combination ofanti-V[38.2 (F23.2) and anti-V[313 
(MR 12-4) mAbs (100 p~g of each antibody per mouse), and in experi- 
ment 2, i.v., with 400 p~g of the control peptide MBP 41-58 or Acl-9 
to deplete Acl-9-specific T cells. Mice were scored daily for symptoms 
of EAE until days 60 and 55, respectively. 
*P values between the control and Acl-9-<iepleted  group was P <0.001, 
and was calculated  using the chi-square test with Yates collection. 
1614  Regulatory T Cells and Self-Tolerance During the course of EAE  (on day 14), mice were injected 
intravenously  with  400  ~g of Acl-9  or MBP  41-58  pep- 
tide in saline  (Table  4).  Mice  tolerized with Acl-9  recov- 
ered  relatively  quickly  (days  23-25),  whereas  five  out  of 
five mice in the  control  group  tolerized with  MBP  41-58 
contracted chronic disease and had tail paralysis beyond day 
35. Thus, chronic EAE in Treg-depleted mice still seems to 
be driven by the presence ofAcl-9--specific T  cells. 
Discussion 
We have attempted to determine  the importance  of the 
activation of VI314 and VI33 regulatory CD4 T  cells in the 
development and course of EAE in the  (SJL  ×  B10.PL)F1 
mice.  In this  strain,  TCR-peptide~specific  T  cells specific 
for  the  immunodominant  TCR  13-chain  peptide  B5  are 
physiologically  induced  via antigenic  stimulation,  without 
any  exogenous  challenge  with  the  TCR  peptide.  Impor- 
tantly,  here we  have shown  that the  deletion/blocking  of 
CD4  V{B14+/V{B3 +  Treg  cells from the  peripheral  T  cell 
repertoire leads to an increase in severity of EAE and poor 
recovery from disease in F1 mice. 
TCR Peptide B5-specific T  Cells Predominantly Expressing 
the  V~14  Gene  Segment Are Naturally  Revealed in  (SJL  X 
BIO.PL)F1  Mice Recovering from  Antigen-induced  EAE. 
Demonstration  of the induction  of TCR  peptide B5-reac- 
tive  CD4  T  cells  during  the  course  of antigen-induced 
EAE  suggests  that  a  determinant  within  the  B5  peptide 
(amino  acids  76-101)  from the  V[38.2  chain  of the  T  cell 
receptor  is  physiologically  processed  and  presented  in  a 
class  II  (I-A  u)  context.  There  are  two  other  peptides  (B2 
and B4) from the same V[3 chain that are capable of induc- 
ing T  cell proliferative responses when the peptide form is 
used  for  immunization  (17).  These  latter  peptides  seem- 
ingly are not  naturally  processed  and  presented,  at least in 
the presence orB5, because spontaneous T  cell reactivity to 
them is not detected during the course of EAE. 
Determinant(s)  within the B5 peptide appear to be dom- 
inant:  first,  LN cells from mice  challenged  with  recombi- 
nant  single-chain  TCR  molecules  containing  the  entire 
V[38.2  chain,  respond  to B5  in in vitro proliferative recall 
assays and  not  to  other  TCP,.  peptides  (Kumar,  V.  et  al., 
manuscript  submitted  for publication);  second,  spleen  cells 
from naive animals are capable of stimulating B5-reactive T 
cell  clones  in  vitro  in  the  absence  of exogenous  peptide 
(18).  Thus,  APCs  appear to constitutively process and po- 
tentially present  B5  in  vivo.  In view  of the  prevalence  of 
the  TC1L V[38  family in peripheral  T  cells  (15-30%),  it is 
not surprising that TCR  V[38 peptides are generated which 
are capable of binding to MHC  molecules in vivo. Among 
these,  B5  seems to possess the  appropriate  combination  of 
availability and affinity of binding to A u to render it domi- 
nant.  Another  possible  interpretation  is  that  some  other 
molecule(s)  on the surface of splenic APC  could be cross- 
reactive (26)  and mimic the B5 TC1K determinant.  We are 
currently examining these issues. 
Typically,  dominant  determinants  on  self-antigens  in- 
duce thymic tolerance  (23). Thus, why is the T  cell reper- 
toire directed against the dominant TCP, peptide B5 still in- 
tact? Are these TCR.-peptide-MHC  complexes not present 
in the thymus or do they fail to mediate negative selection? 
It is hkely that if determinants  in the B5  region were  able 
to be processed and presented by the thymic APCs,  T  cells 
expressing only high  affinity TCR  would  be deleted spar- 
ing  the  low  affinity TCR-bearing  T  cells to be positively 
selected.  Our data demonstrate  an inability to induce  neo- 
natal  tolerance  to  B5  and  is  consistent  with  the  idea  that 
most B5-specific T  cells are not deleted,  but rather may be 
primed,  as  has  recently  been  reported  (27).  These  results 
are similar to a recent report in the rat model where neona- 
tal  tolerance  to  the  CDI<2  peptide  does  not  lead  to  a 
change in the  course of EAE  (28).  However, rats tolerized 
as adults to this peptide contract severe disease (28). 
V1814 and~or Vj83 CD4 Treg Cells Are Crucial  for Sponta- 
neous Recovery  from Antigen-induced EAE.  Delayed  recovery 
from Acl-9-induced  EAE in F1  mice after treatment with 
Treg-reactive anti-V[3  mAbs indicates  that the presence of 
TCP,-peptide-specific  CD4  T  cells  is  crucial  for  a  quick 
spontaneous  recovery  in  these  mice.  It  is  irtteresting  that 
rats tolerized as adults to the VI3 8 CDP,2 peptide contract 
severe EAE but this tolerance did not result in chronic dis- 
ease  or  prolonged  recovery  (28).  Oligoclonality  in  TCP,. 
V[3-gene  usage  by spontaneously  primed  CD4  Treg  cells 
was further  confirmed by the  demonstration  that the most 
significant  delay  in  recovery  occurred  in  animals  treated 
with  both  anti-V[314  and  anti-V[33  rnAbs.  Interestingly, 
most  of the  animals,  despite  treatment  with  both  mAbs, 
were able to partially recover. There are at least four expla- 
nations  for this  finding;  (a)  incomplete  depletion  of Treg 
expressing V[314  or VI33;  (b)  emergence  of CD4  Treg us- 
ing  alternate  VI3  gene  segments;  (c)  emergence  of T  cells 
specific  for  other  subdominant  or  cryptic  MBP  determi- 
nants which induce Th2 cells, leading to immune deviation 
in  a  Th2  direction,  accompanied  by  down-regulation  of 
Thl;  (d) recruitment  of CD8 T  cells, which become inde- 
pendent of CD4 Treg in the down-modulation  of enceph- 
alitogenic potential.  These hypotheses are not mutually ex- 
clusive and are currently being examined. 
Finally, relapses in some of the Treg-depleted animals, as 
well  as  the  occurrence  of chronic  EAE  in  a  mouse  strain 
that normally gets an acute episode of EAE, suggest that the 
spontaneous  chronic  autoimmune  disease  course  found  in 
some  experimental  models  or  in  humans  could  reflect  a 
crucial  defect  in  tight  regulation.  In  monozygotic  twins, 
frequently only one suffers from chronic  autoimmune  dis- 
ease: in such cases defective regulation  could be decisive in 
the  manifestation  of the  disease.  Conversely,  stronger  and 
more efficient regulatory  erectors may exist in EAE-resis- 
rant  mouse  strains,  protecting  them  from antigen-induced 
autoimmunity. 
Chronidty  of EAE in  Treg-depleted Mice Seems To Be De- 
pendent on the Presence of T  Cells Specific  for the lmmunodomi- 
nant Determinant Acl-9.  In  (SJL  X  B10.PL)F1  mice,  the 
initial  response  to  MBP  focuses  on  the  immunodominant 
1615  Kumar et al. determinant  Acl-9  within  the  NH2-terminal  fragment. 
However, owing to determinant spreading (24), T  cells re- 
active  to  other  subdominant  determinants,  for  example, 
81-100/A  s,  and  121-140/A  u are revealed in splenic  T  cell 
proliferation assays.  It has been shown that challenge with 
certain  subdominant  peptides  in  strong  adjuvants  (CFA 
and PTx),  or adoptive transfer of in vitro-activated T  cells 
into  naive  mice  result  in EAE  (Kumar,  V.,  unpublished 
observation; 29). It is not yet clear whether in vivo-primed 
T  cells  reactive to these latter  determinants  are critical for 
the chronic course of EAE. Our findings in Acl-9~pecific 
T  cell-depleted  mice suggest that  the  continued presence 
of the  initially  dominant  peptide-reactive  T  cells  may be 
required  for sustaining  chronic EAE in this model.  How- 
ever,  it  is  likely  that  in  the  chronic-relapsing  model  of 
EAE, recruited T  cells  reactive to newly revealed determi- 
nants could participate  in the disease,  as suggested recently 
in the SJL mouse (29). 
How Do the CD4  Treg Regulate Responses to MBP?  It  is 
likely that activated V[314 + regulatory T  cells  traffic to in- 
flammatory sites  in the  central  nervous  system and locally 
down-regulate Acl-9-specific responses  through secretion 
of modulatory  cytokines,  for example,  TGF-[3,  IL-4,  or 
IL-10  (reviewed  in  references  4  and  5).  Consistent  with 
this  notion,  the presence  of V[314 mP,.NA in central ner- 
vous system tissue during recovery from EAE, around day 
12,  has recently been demonstrated  in  (PL/J  ×  SJL)  mice 
(30).  Preliminary analysis of the  cytokine secretion profile 
of CD4 Treg reveals  that these  cells  are Th0-1ike  in their 
ability to secrete IL-2 and IFN-% as well as IL-4 and IL-5 
(Kumar, V., unpublished observations). 
CD8  deletion  experiments  suggest  that  once  activated, 
the  regulatory B5-reactive  CD4 +  T  cells  recruit  CD8 + 
T  cells which ultimately down-regulate  encephalitogenic 
T  cells  (18).  The  CD8  cells  can  recognize  distinct  TCR 
determinants  in an MHC  class  I context,  displayed on the 
surface of MBP-specific effector cells  (31).  Recognition of 
the  activated,  encephalitogenic  V[38.2 +  effector  cells  by 
TCP,-peptide-specific  CD8 +  T  cells  may  thus  be  one 
pathway  of specific  regulation.  Indeed,  we  have  recently 
characterized a potential  class  I determinant  on the V[38.2 
chain distinct  from B5.  Mice vaccinated with this  10-mer 
peptide are completely protected from MBP/Acl-9-induced 
EAE in an unusual dose-related fashion, the protective dose 
being  very  low  (Kumar,  V.,  unpublished  observations). 
Other experiments in mice devoid of CD8 ÷ T  cells,  either 
by anti-CD8  treatment  or CD8  gene  targeting,  have  also 
shown that CD8 cells play an important role in regulating 
further episodes of EAE (32, 33). 
In conclusion, it is likely that TCP, V[314 + CD4 regula- 
tory T  cells  are  an  essential  part  of a  physiological T  cell 
regulatory circuit that  establishes  tolerance  to self MBP in 
the  (SJL  X  B10.PL)F1  mouse  (34).  It appears  that  disrup- 
tion  of this  cellular  circuitry  can  result  in  an  anomalous 
persistence and chronicity of autoimmune disease. 
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